Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been given an average rating of “Moderate Buy” by the eleven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $19.6250.

BCYC has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Truist Financial assumed coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a “hold” rating and a $10.00 price objective on the stock. Finally, Jefferies Financial Group raised Bicycle Therapeutics to a “strong-buy” rating in a report on Tuesday, February 17th.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock opened at $5.30 on Wednesday. The firm has a 50-day moving average of $6.09 and a 200-day moving average of $6.88. Bicycle Therapeutics has a 52-week low of $5.03 and a 52-week high of $10.84. The stock has a market cap of $367.66 million, a PE ratio of -1.46 and a beta of 1.65.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares of the company’s stock, valued at $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alethia Young sold 4,334 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the sale, the chief financial officer owned 87,081 shares in the company, valued at $565,155.69. The trade was a 4.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 38,029 shares of company stock valued at $251,966. 8.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Assetmark Inc. boosted its holdings in shares of Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after purchasing an additional 1,552 shares in the last quarter. Clearstead Advisors LLC lifted its position in shares of Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after buying an additional 3,262 shares during the last quarter. Brooklyn Investment Group acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at about $69,000. Ausdal Financial Partners Inc. bought a new position in Bicycle Therapeutics in the second quarter valued at about $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new position in Bicycle Therapeutics during the fourth quarter worth about $71,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.